Sugi Predict

Sugi Predict / Compounds / SCHEMBL19616489

SCHEMBL19616489

SCHEMBL19616489

CSc1nc2c(c(N3CCN(C(=O)OCc4ccccc4)CC3)n1)CCN(C(=O)OC(C)(C)C)C2

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TMEM97 Q5BJF2 6/20 0.46
▸ SIGMAR1 Q99720 6/20 0.46
▸ MTOR P42345 2/20 0.44
▸ TLR9 Q9NR96 4/20 0.43
▸ TLR7 Q9NYK1 2/20 0.43
▸ ACHE P22303 1/20 0.43
▸ PARP1 P09874 2/20 0.41
▸ P2RX3 P56373 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ TNKS2 Q9H2K2 1/20 0.41
▸ PARP2 Q9UGN5 1/20 0.41
▸ BACE1 P56817 1/20 0.40
▸ SLC29A1 Q99808 1/20 0.40
▸ PTGDR2 Q9Y5Y4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30421626 0.95 TLR9 (0.43) TMEM97SIGMAR1MTORTLR9TLR7
SCHEMBL19637801 0.93 TMEM97 (0.45) TMEM97SIGMAR1MTORTLR9TLR7
SCHEMBL22010705 0.92 TMEM97 (0.45) TMEM97SIGMAR1MTORTLR9TLR7
SCHEMBL21315070 0.90 TMEM97 (0.45) TMEM97SIGMAR1MTORMEN1KMT2A
SCHEMBL22479711 0.90 MTOR (0.42) TMEM97SIGMAR1MTORTLR9TLR7
SCHEMBL19616716 0.88 TMEM97 (0.47) TMEM97SIGMAR1MTORTLR9TLR7
SCHEMBL19616526 0.87 TMEM97 (0.43) TMEM97SIGMAR1MEN1KMT2ASLC29A1
SCHEMBL30565842 0.87 MTOR (0.40) TMEM97SIGMAR1MTORPARP1P2RX3
SCHEMBL30835161 0.87 TMEM97 (0.41) TMEM97SIGMAR1MTORPARP1P2RX3
SCHEMBL19947629 0.86 ACHE (0.44) MTORTLR9TLR7ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4501932-A2 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2025-02-05 — — EP disclosed
EP-3880208-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-11-20 — — EP disclosed
CN-111989321-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2024-05-14 — — CN disclosed
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 — — US disclosed
CN-113544128-B KRAS-G12C inhibitors 微境生物医药科技(上海)有限公司 2023-12-08 — — CN disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
EP-3710439-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-02-15 — — EP disclosed
EP-3710439-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-02-15 — — EP disclosed
US-11267812-B2 KRAS G12C inhibitors Mirati Therapeutics, Inc. (US) 2022-03-08 — — US disclosed
WO-2020101736-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2020-05-22 — — WO disclosed
US-10647715-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2020-05-12 — — US disclosed
US-10633381-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2020-04-28 — — US disclosed
US-20190270743-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2019-09-05 — — US disclosed
US-20190144444-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2019-05-16 — — US disclosed
EP-3458445-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2019-03-27 — — EP disclosed
US-10125134-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2018-11-13 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190144444-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TMEM97 3851/4885SIGMAR1 4812/4885MTOR 1106/4885
US-10633381-B2 KRas G12C inhibitors KRAS, NRAS, HRAS TMEM97 3851/4885SIGMAR1 4812/4885MTOR 1106/4885
US-11267812-B2 KRAS G12C inhibitors KRAS, NRAS, HRAS TMEM97 3851/4885SIGMAR1 4812/4885MTOR 1106/4885
US-10647715-B2 KRas G12C inhibitors KRAS, NRAS, HRAS TMEM97 3851/4885SIGMAR1 4812/4885MTOR 1106/4885
US-10125134-B2 KRas G12C inhibitors KRAS, NRAS, HRAS TMEM97 3851/4885SIGMAR1 4812/4885MTOR 1106/4885
US-20240101553-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TMEM97 3851/4885SIGMAR1 4812/4885MTOR 1106/4885
US-20190270743-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TMEM97 3851/4885SIGMAR1 4812/4885MTOR 1106/4885
US-20180072723-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TMEM97 3851/4885SIGMAR1 4812/4885MTOR 1106/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TMEM97 3851/4885SIGMAR1 4812/4885MTOR 1106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.